Key result
MicroRNAs play an important role in the pathogenesis of diabetic neuropathy and hold promise as both biomarkers and therapeutic targets, particularly when packaged within extracellular vesicles.
Why the study?
The exact pathophysiological mechanisms of diabetic neuropathy remain unclear, and the roles of microRNAs as biomarkers and potential therapeutic targets warrant review.
This review highlights the potential of miRNAs, particularly when packaged in extracellular vesicles, as novel biomarkers and therapeutic targets for diabetic neuropathy.
Answers are grounded in this paper and cite their sources.
Supports microRNA research in diabetic neuropathy; leaves open clinical translation as biomarkers or therapies pending validation.
Diabetic neuropathy (DN) is the most prevalent chronic complication of diabetes mellitus. The exact pathophysiological mechanisms of DN are unclear; however, communication network dysfunction among axons, Schwann cells, and the microvascular endothelium likely play an important role in the development of DN. Mounting evidence suggests that microRNAs (miRNAs) act as messengers that facilitate intercellular communication and may contribute to the pathogenesis of DN. Deregulation of miRNAs is among the initial molecular alterations observed in diabetics. As such, miRNAs hold promise as biomarkers and therapeutic targets. In preclinical studies, miRNA-based treatment of DN has shown evidence of therapeutic potential. But this therapy has been hampered by miRNA instability, targeting specificity, and potential toxicities. Recent findings reveal that when packaged within extracellular vesicles, miRNAs are resistant to degradation, and their delivery efficiency and therapeutic potential is markedly enhanced. Here, we review the latest research progress on the roles of miRNAs as biomarkers and as potential clinical therapeutic targets in DN. We also discuss the promise of exosomal miRNAs as therapeutics and provide recommendations for future research on miRNA-based medicine.
No takes yet. Share an insight, caveat, or question.
Fan et al. (2020) conducted a review in Diabetic Neuropathy. microRNAs was evaluated. MicroRNAs play an important role in the pathogenesis of diabetic neuropathy and hold promise as both biomarkers and therapeutic targets, particularly when packaged within extracellular vesicles.
Synapse has enriched 10 related papers. Consider them for comparative context: